The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications

Lancet. 2019 Aug 3;394(10196):420-431. doi: 10.1016/S0140-6736(19)31266-8.


Developments in high-throughput microbial genomic sequencing and other systems biology techniques have given novel insight into the potential contribution of the gut microbiota to health and disease. As a result, an increasing number of diseases have been characterised by distinctive changes in the composition and functionality of the gut microbiota; however, whether such changes are cause, consequence, or incidental to the disease in question remains largely uncertain. Restoration of the gut microbiota to a premorbid state is a key novel therapeutic approach of interest, and faecal microbiota transplantation-the transfer of prescreened stool from healthy donors into the gastrointestinal tract of patients-is gaining increasing importance in both the clinical and research settings. At present, faecal microbiota transplantation is only recommended in the treatment of recurrent Clostridioides difficile infection, although a large number of trials are ongoing worldwide exploring other potential therapeutic indications.

Publication types

  • Review

MeSH terms

  • Clostridium Infections / therapy*
  • Fecal Microbiota Transplantation / trends*
  • Gastrointestinal Microbiome
  • Humans
  • Practice Guidelines as Topic
  • Randomized Controlled Trials as Topic
  • Treatment Outcome